Fig. 6: Alisertib reduces c-MET expression levels and impairs CSC features in vivo. | British Journal of Cancer

Fig. 6: Alisertib reduces c-MET expression levels and impairs CSC features in vivo.

From: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells

Fig. 6

a Western blot analysis of total (n = 3) and phosphorylated (n = 4) levels of LATS-1, YAP1, ERK and MOB-1 in tumors treated with alisertib and/or cetuximab, normalized to the control. Results are plotted as the average ± SD of all the biological replicates, **p < 0.01, one-way ANOVA. Differences in p-ERK expression were compared by using Welch and Brown-Forsythe ANOVA since residuals did not meet the homoscedasticity criteria of one-way ANOVA. b Analysis of SOX2 expression levels in tumors after treatment with alisertib and/or cetuximab, normalized to non-treated tumors. Results are plotted as the average ± SD of all the biological replicates, *p < 0.05 (n = 4), one-way ANOVA. c Assessment of ALDH1 activity after treatment with alisertib and/or cetuximab, normalized to non-treated tumors. Results are plotted as the average ± SD of all the biological replicates, *p < 0.05 (n = 4), one-way ANOVA. d. Evaluation of the gene expression levels of SOX2 in tumors after being treated with alisertib and/or cetuximab. Results are plotted as the average ± SD of all the biological replicates, *p < 0.05 (n = 4), one-way ANOVA.  CTR Control, ALS Alisertib, CTX Cetuximab, COM Combined.

Back to article page